Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
GMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.24 - $27.91
Previous CloseN/A
Volume229.76K
Average Volume (3M)1.25M
Market Cap
$15.87B
Enterprise Value$9.96B
Total Cash (Recent Filing)$18.37B
Total Debt (Recent Filing)$937.88M
Price to Earnings (P/E)13.4
Beta0.52
Next Earnings
Nov 06, 2025EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.54
Shares Outstanding641,588,130
10 Day Avg. Volume1,418,585
30 Day Avg. Volume1,250,336
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue0.44
Enterprise Value/Gross Profit0.46
Enterprise Value/Ebitda1.30
Forecast
1Y Price Target
$32.75Price Target Upside19.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGenmab recorded a diluted net income of $5.42 per share, which exceeded the previously forecasted $4.13 per share.
Product DevelopmentThe potential FDA approval for the combination of epcoritamab + rituximab for treating relapsed or refractory follicular lymphoma is highlighted as a significant upcoming catalyst.
Revenue GrowthGenmab generated $925M in revenue for the quarter, with DARZALEX royalties coming in at $638M, surpassing the estimate of $606M.
Bears Say
Competitive ChallengesData to date in NSCLC for acasunlimab has been lackluster in a highly competitive space.
Patent RisksThe outlook remains guarded given uncertainty as to whether Genmab can overcome the Darzalex patent cliff by 2030.
Genmab News
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $17.23 and its highest was $27.91 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is $15.87B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Nov 06, 2025 which is in 61 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Aug 07, 2025. The company reported $0.542 earnings per share for the quarter, beating the consensus estimate of $0.399 by $0.143.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 0.45.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 641,588,130 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.542 in its last earnings report, beating expectations of $0.399. Following the earnings report the stock price went up 5.486%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GMAB
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.75 (19.61% Upside)
$32.75 (19.61% Upside)
Blogger Sentiment
Neutral
GMAB Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 425.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.20%
12-Months-Change
Fundamentals
Return on Equity
26.08%
Trailing 12-Months
Asset Growth
16.47%
Trailing 12-Months
Company Description
Genmab A/S
Genmab (GMAB) is a leading international biotechnology company specializing in the development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab focuses on creating innovative treatments that harness the body's immune system to combat malignancies. The company is known for its proprietary technologies, such as the DuoBody platform, which enables the development of bispecific antibodies, and has a robust pipeline of product candidates, including its flagship drug, Darzalex (daratumumab), used in multiple myeloma treatment.
GMAB Company Deck
GMAB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance and promising clinical trial results, particularly for EPKINLY and Rina-S. The company is strategically investing in its pipeline and expanding its market presence. However, challenges such as the discontinuation of HexaBody-OX40 and potential regulatory hurdles were noted.View all GMAB earnings summariesGMAB Stock 12 Month Forecast
Average Price Target
$32.75
▲(19.61% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.86% Mutual Funds
2.95% Other Institutional Investors
95.41% Public Companies and
Individual Investors